Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of JST-018 in Healthy Adults
NCT07595458Phase 1Recruiting
- Sponsor
- Evotec SE
- Start
- Jun 2026
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Orthopoxvirus infection comparing JST-018 Investigational Product with Placebo (2 arms). Primary endpoint: Safety and tolerability at Week 48. Started Jun 2026; status: recruiting.
02
Drugs
JST-018
03
Conditions
Orthopoxvirus infection
Beyond the preview
Go deeper on NCT07595458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595458.